Get your patient on Wegovy (Semaglutide)

Wegovy Savings Card, Coupon & Coverage 2026

50–80%
of the top 10 commercial plans cover Wegovy
38%
of plans require PA
$0/mo
with Wegovy Savings Card
16
savings & assistance programs
Compare GLP-1 Alternatives
See how Wegovy stacks up on access, cost, and PA burden — the factors that affect whether your patient can actually get on therapy.
Access MetricWegovySemaglutidezepboundmounjaroozempicrybelsus
Plan Coverage% of commercial plans50–80%Best
PA Required% of plans requiring PA38%
Copay w/ SavingsWith manufacturer card
$0
Savings ProgramsTotal available16Most
CopayFoundationhub
Approved IndicationsFDA-approved uses
Weight ManagementCardiovascular Risk
Get better comparisons with Prescriber.AI
See which alternative has the best coverage, lowest PA burden, and best savings for your patient's specific insurance.
See all comparisons →

Insurance Coverage

See specific coverage requirements for your patient's insurance plan.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
UnitedHealthcare (UHC)Wegovy
Covered on 4 commercial plans
PA (4/4) · Step therapy (0/4) · Qty limit (0/4)
View full coverage details
Aetna HealthWegovy
Covered on 5 commercial plans
PA (1/5) · Step therapy (0/5) · Qty limit (1/5)
View full coverage details
CIGNAWegovy
Covered on 4 commercial plans
PA (0/4) · Step therapy (0/4) · Qty limit (0/4)
View full coverage details
Coverage data sourced from MMIT. Updated monthly.

Savings & Copay Programs

Help your patients reduce out-of-pocket costs for Wegovy.
$0/fill
COPAY CARD
Wegovy Savings CardEligible commercially-insured patients may pay as little as $0/fill. Check program terms and enrollment eligibility.

Prior Authorization38% of plans require PA7 forms
Download the right PA form for your patient's insurance plan.

Most recent Wegovy prior authorization forms

Aetna - Louisiania Prior Authorization Request FormUpdated May 11, 2026
Aetna - Medical Exception/Prior Authorization/Precertification Request for Prescription MedicationsUpdated May 11, 2026
Humana - General Prior Authorization FormUpdated May 11, 2026
Independence Health - Select Formulary Prior Authorization Form Updated May 11, 2026
Kaiser Permanente of Colorado - Medicare Medication Request form (MRF)Colorado · Updated May 11, 2026
View all PA forms for Wegovy
Brand Resources
Formulary InformationFormulary Information resource
Service Request Form Service Request Form resource
onehub-banner
Let us handle your prior authsJust enter your patient's info and we'll:
  • Verify eligibility with the payer.
  • Pull the right PA forms directly from the payer.
  • Submit, track & send live updates to your dashboard.
Utilize patient records to autofill forms with our AI in seconds.
Free to start · HIPAA compliant
Prescribing Information
Indications
  • To reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight.
  • To reduce excess body weight and maintain weight reduction long term in: Adults and pediatric patients aged 12 years and older with obesity.
  • Adults with overweight in the presence of at least one weight-related comorbid condition.
Dosing Titration
0.25
0.25 mgFirst 4 weeksTitration
2.4
2.4 mg≥4 weeks laterMax dose
Common Side Effects
Nausea
44%
Diarrhea
30%
Vomiting
24%
Constipation
24%
Abdominal Pain
20%
Contraindications
  • A personal or family history of MTC or in patients with MEN 2.
  • A prior serious hypersensitivity reaction to semaglutide or to any of the excipients in WEGOVY injection or WEGOVY tablet. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with WEGOVY.
Full FDA Prescribing Information
Access the complete FDA-approved prescribing label for Wegovy, including approved indications, recommended dosage & administration schedules, contraindications, warnings & precautions, adverse reactions, drug interactions, and use in specific populations.

Resources

Dosage & administration

DOSAGE AND ADMINISTRATION

In patients with diabetes, monitor blood glucose prior to starting and during WEGOVY treatment. (2.1 )

WEGOVY Injection

  • Administer WEGOVY injection once weekly as an adjunct to diet and increased physical activity, on the same day each week, at any time of day, with or without meals. (2.1 )
  • Inject subcutaneously in the abdomen, thigh, or upper arm. (2.1 )
  • Initiate at 0.25 mg once weekly for 4 weeks. Then follow the dosage escalation schedule in Table 1, titrating every 4 weeks to achieve the maintenance dosage. (2.2 )
  • The usual recommended maintenance dosage of WEGOVY injection is 2.4 mg once weekly. Refer to the full PI for maintenance dosages based on the indication. (2.2 )

WEGOVY Tablets

  • Take WEGOVY tablets orally once-daily on an empty stomach in the morning with water (up to 4 ounces). Do not take with other liquids besides water (2.1 ).
  • Swallow tablets whole. Do not split, crush, chew or dissolve. (2.1 )
  • After taking WEGOVY tablet wait at least 30 minutes before eating food, drinking beverages or taking other oral medications. (2.1 )
  • Initiate WEGOVY tablet with a dosage of 1.5 mg once daily for 30 days. Then follow the dosage escalation schedule, titrating every 30 days to achieve the maintenance dosage. (2.2 )
  • The recommended maintenance dosage of WEGOVY tablets is 25 mg orally once daily for cardiovascular risk reduction and weight reduction in adults. (2.3 )

2.1 Important Monitoring and Administration Instructions

In patients with diabetes mellitus, monitor blood glucose prior to starting WEGOVY and during WEGOVY treatment [see Warnings and Precautions (5.4 )] .

Administer WEGOVY in combination with a reduced-calorie diet and increased physical activity.

WEGOVY Injection

  • Prior to initiation of WEGOVY injection, train patients on proper injection technique. Refer to the accompanying Instructions for Use for complete administration instructions with illustrations.
  • Visually inspect the WEGOVY injection prior to each administration. Only use if the solution is clear, colorless, and contains no particles.
  • Administer WEGOVY injection once weekly, on the same day each week, at any time of day, with or without meals.
  • Inject WEGOVY subcutaneously in the abdomen, thigh, or upper arm. The time of day and the injection site can be changed without the need for a dosage modification.

WEGOVY Tablets

  • Take one WEGOVY tablet orally once daily on an empty stomach in the morning with water (up to 4 ounces). Do not take WEGOVY tablets with other liquids besides water [see Clinical Pharmacology (12.3 )] .
  • Swallow tablets whole. Do not split, crush, chew or dissolve in any solution.
  • After taking a WEGOVY tablet, wait at least 30 minutes before eating food, drinking beverages or taking other oral medications [see Clinical Pharmacology (12.3 )] .

2.2 Recommended Dosage for WEGOVY Injection

Recommended Starting Dosage and Dosage Escalation of WEGOVY Injection for All Approved Indications

  • The recommended starting dosage of WEGOVY injection is 0.25 mg administered subcutaneously once weekly.
  • Follow the dosage escalation in Table 1 to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions (5.6 ), Adverse Reactions (6.1 )] .
  • If patients do not tolerate a dose during dosage escalation, consider delaying dosage escalation for 4 weeks.

Table 1. Recommended Starting Dosage and Dosage Escalation of WEGOVY Injection for All Approved Indications in Adults and Pediatric Patients Aged 12 Years and Older

Weeks

Once-weekly Subcutaneous Injection Dosage

Starting Dosage

1 through 4

0.25 mg

Dosage
Escalation

5 through 8

0.5 mg

9 through 12

1 mg

13 through 16

1.7 mg

Maintenance
Dosage

17 and onward

See the indication below for the recommended maintenance dosage(s)

Recommended Maintenance Dosage of WEGOVY Injection for All Approved Indications

Cardiovascular Risk Reduction in Adults

  • The maintenance dosage of WEGOVY injection for cardiovascular risk reduction in adults is either 2.4 mg (recommended) or 1.7 mg once weekly.
  • Consider treatment response and tolerability when selecting the maintenance dosage [see Adverse Reactions (6.1 ), Clinical Studies (14.1 )] .

Weight Reduction in Adults

  • The maintenance dosage of WEGOVY for weight reduction in adults is either 1.7 mg or 2.4 mg (recommended) injected subcutaneously once weekly.
  • For patients who tolerate the 2.4 mg dosage for at least 4 weeks and additional weight reduction is clinically indicated, the dosage may be increased to a maximum dosage of 7.2 mg subcutaneously once weekly.
  • Consider treatment response and tolerability when selecting the maintenance dosage [see Adverse Reactions (6.1 ), Clinical Studies (14.2 )].

Weight Reduction in Pediatric Patients Aged 12 Years and Older

  • The maintenance dosage of WEGOVY injection for weight reduction in pediatric patients aged 12 years and older is either 2.4 mg (recommended), 1.7 mg once weekly.
  • Consider treatment response and tolerability when selecting the maintenance dosage [see Adverse Reactions (6.1 ), Clinical Studies (14.3 )] .

Noncirrhotic MASH with Moderate to Advanced Liver Fibrosis in Adults

  • The recommended maintenance dosage of WEGOVY injection for the treatment of noncirrhotic MASH with moderate to advanced liver fibrosis in adults is 2.4 mg injected subcutaneously once weekly. If patients do not tolerate the maintenance dosage of 2.4 mg once weekly, the dosage can be decreased to 1.7 mg once weekly. Consider reescalation to 2.4 mg once weekly [see Adverse Reactions (6.1 ), Clinical Studies (14.4 )] .

2.3 Recommended Dosage of WEGOVY Tablets

Recommended Dosage of WEGOVY Tablets for Cardiovascular Risk Reduction or Weight Reduction in Adults

  • The recommended starting dosage of WEGOVY tablets is 1.5 mg taken orally once daily. Follow the dosage escalation in Table 2 to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions (5.6 ), Adverse Reactions (6.1 )] .
  • If patients do not tolerate a dose during dosage escalation, consider delaying dosage escalation.
  • The recommended maintenance dosage of WEGOVY tablets is 25 mg orally once daily.
  • If patients do not tolerate the 25 mg once daily maintenance dosage, consider switching to WEGOVY injection 1.7 mg once weekly [see Dosage and Administration (2.5 )] .

Table 2. Recommended Dosage of WEGOVY Tablets for Cardiovascular Risk Reduction or Weight Reduction in Adults

Days

Once Daily Tablet

Dosage

Starting Dosage

1 through 30

1.5 mg

Dosage Escalation

31 through 60

4 mg

61 through 90

9 mg

Maintenance Dosage

91 and onward

25 mg

2.4 Recommendations Regarding Missed Dose(s)

WEGOVY Injection

  • If one dose of WEGOVY injection is missed and the next scheduled dose is:
  • More than 2 days away, administer WEGOVY injection as soon as possible.
  • Less than 2 days away do not administer the WEGOVY injection dose. Resume dosing on the regularly scheduled day of the week.
  • If 2 or more consecutive doses of WEGOVY injection are missed, resume dosing as scheduled or, if needed, reinitiate WEGOVY injection and follow the dosage escalation schedule, which may reduce the occurrence of gastrointestinal adverse reactions associated with reinitiation of treatment [see Dosage and Administration (2.2 )].

WEGOVY Tablets

If a dose of WEGOVY tablets is missed, skip the missed dose and take the next dose the following day.

2.5 Switching Between WEGOVY Injection and WEGOVY Tablets

Switching from WEGOVY Injection to WEGOVY Tablets

  • Patients taking WEGOVY 2.4 mg injection for cardiovascular risk reduction or weight reduction in adults may switch to WEGOVY 25 mg tablets.
  • One week after discontinuing WEGOVY 2.4 mg injection, initiate 25 mg of WEGOVY tablets orally once daily.

Switching from WEGOVY Tablets to WEGOVY Injection

  • Patients may switch from WEGOVY 25 mg tablets to WEGOVY injection.
  • The day after discontinuing WEGOVY tablets 25 mg once daily, initiate WEGOVY 2.4 mg subcutaneous injection once weekly. For patients who do not tolerate WEGOVY 25 mg tablets, consider switching to WEGOVY 1.7 mg injection.
  • If additional weight reduction is needed in patients with type 2 diabetes mellitus treated with WEGOVY 25 mg tablets, consider switching to WEGOVY 1.7 mg injection and follow the recommended dosage escalation for WEGOVY injection [see Dosage and Administration (2.2 ), Use in Specific Populations (8.6 ), Clinical Pharmacology (12.3 )].

PubMed™ news

5 most recent articles for Wegovy, view all articles on PubMed™
Show the latest PubMed™ articles for Wegovy

Frequently Asked Questions